Introduction
============

Ovarian cancer is the most challenging gynecological malignancy to be treated and the fifth most common cause of cancer-related deaths among females \[[@B1]\]. Only 40--60% of patients with ovarian cancer can achieve complete remission after staging surgery followed by paclitaxel with carboplatin chemotherapy \[[@B2]\]. There are several chemotherapy regimens for recurrent ovarian cancer (ROC), which should be selected according to platinum sensitivity \[[@B3]\]. Treatment of platinum-sensitive ROC is based on combination therapies, including platinum agents (carboplatin \[Paraplatin®; Bristol-Myers Squibb, Princeton, NJ, USA\] and cisplatin \[Platinol®; Bristol-Myers Squibb\]). However, combination chemotherapy has additional concerns of increased adverse effects such as bone marrow depression or nephrotoxicity. In platinum-resistant ROC, single-agent chemotherapy is considered.

Doxorubicin has been used for ROC; however, its use is limited owing to adverse effects, particularly cardiotoxicity, which increases with cumulative doses \[[@B4]\]. Hence, pegylated liposomal doxorubicin (PLD; Caelyx®; TTY Biopharm Co., Ltd., Taipei, Taiwan), with an increased circulating half-life and a better toxicity profile, including cardiotoxicity and myelosuppression, through its liposomal envelope leads to low doses of free doxorubicin in the normal tissue \[[@B5]\]. The trial of Caelyx in Platinum Sensitive Ovarian (CALYPSO) patients conducted by the Gynecological Cancer InterGroup (GCIG) showed that PLD combined with carboplatin (PLD-C) had better progression-free survival (PFS) and similar overall survival (OS) compared with paclitaxel (Taxol®; Bristol-Myers Squibb) and carboplatin in platinum-sensitive ROC \[[@B6]\]. In addition, PLD-C had less severe toxicities, particularly alopecia, compared with paclitaxel and carboplatin \[[@B7]\]. However, the incidence of mucositis and hand-foot syndrome (HFS, palmar-plantar erythrodysesthesia) is high with PLD-C. Certain studies on platinum-resistant ROC have suggested that PLD monotherapy has similar efficacy compared with topotecan or gemcitabine \[[@B8][@B9][@B10]\]. PLD monotherapy showed more frequent HFS and less frequent neutropenia compared with gemcitabine (Gemzar®; Eli Lilly and Company, Indianapolis, IN, USA).

Although PLD has been approved and commercially available in Korea since December 2014, there are no related articles of PLD experience in Korean population yet. Although there was a study in Japan on patients with ROC, the study was phase II clinical trial and most of the patients received only 1 or 2 previous chemotherapy regimens \[[@B11]\]. Patients with advanced ROC with more than 3 previous chemotherapy regimens are more likely to use PLD monotherapy after developing platinum resistance; hence, there is a need for data regarding the effectiveness and safety of PLD monotherapy in real-world clinical settings. To date, there are no retrospective studies on PLD monotherapy in Asian patients. Thus, we aimed to evaluate the efficacy and safety of PLD treatment in Korean patients with ROC.

Materials and methods
=====================

The study protocol was approved by the Institutional Review Board at the Asan Medical Center (IRB No. 2015-0722). A retrospective chart review of consecutively treated patients who begin received either PLD or PLD-C therapy for the treatment of ROC at Asan Medical Center, Seoul, Korea from 1^st^ December 2014 to 20^th^ March 2015 was conducted. Patients were divided on the basis of the platinum-free interval (PFI) from the last chemotherapy (\<6 vs. ≥6 months). For patients with PFI of ≥6 months, PLD-C was administered as treatment for platinum-sensitive ROC. A dose of 50 mg/m^2^ PLD was administered as an intravenous infusion in PLD and PLD-C group. In case of PLD-C, patients received carboplatin add at a dose of 5 areas under curve (AUC). The treatment was repeated every 28 days and was delayed in case of unacceptable toxicities. Only those patients who received treatment at least 2 times were included in the analysis. Chemotherapy was basically administered for 6 consecutive cycles and then continued until disease progression. Cancer antigen 125 (CA-125) levels were monitored at each cycle. Tumor status was assessed using computed tomography after every 3 cycles of chemotherapy and could be assessed before time if any signs of disease progression were observed. Objective response rate (ORR; complete response \[CR\] + partial response \[PR\]) was assessed according to the Response Evaluation Criteria in Solid Tumor (RECIST criteria version 1.1) \[[@B12]\]. CR was the disappearance of all target lesions and PR was \>30% decrease in the sum of the longest diameter of the target lesion; the mean of both these values was considered as ORR. Stable disease (SD) included lesions that were insufficient to constitute as PR or progressive disease (PD). Overall response rate was assessed using ORR and CA-125 response according to the GCIG criteria \[[@B13]\]. Clinical benefit rate (CBR) was defined as CR, PR, or SD. It was impossible to assess OS because the follow-up period was too short.

Patients were monitored for toxicities and allergic reactions following treatment initiation. All patients received additional monitoring for HFS, mucositis, and bone marrow depression at 1 week after every administration in the outpatient clinic. Adverse events were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 4.0). When grade 3 or 4 neutropenia was occurred, granulocyte stimulating factor was given to the patient. In patients with ≥ grade 2 HFS or mucositis, chemotherapy was delayed for up to 2 weeks or until the lesions resolved to grade 0 or 1. In addition, patients with a history of ≥ grade 3 toxicities received 25% dose reduction. The baseline characteristics and adverse events of both groups were compared using χ^2^ tests. The Kaplan-Meier method was used for PFS analysis. All statistical analyses were performed using the SPSS software, version 21.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

A total of 52 patients were eligible for the study criteria and the total follow-up period was 1,108 months (range, 18 to 23 months). All patients were evaluated for response rates. Patient characteristics are summarized in [Table 1](#T1){ref-type="table"}. The mean age was 57.4 years (range, 32 to 74 years); 40 patients had received 155 cycles of PLD monotherapy, and 12 patients had received 84 cycles of PLD-C therapy. Patient\'s age, initial stage, histological subtype, largest lesion, and pretreatment CA-125 levels were similar in both groups. The treatment-free interval were 3.7 months in PLD monotherapy group and 10.7 months in the PLD-C group, respectively (*P*=0.002). And more patients in the PLD monotherapy group had received more than three chemotherapy regimens in the past compared with the PLD-C group (*P*=0.001).

The subgroup responses according to the chemotherapy regimen administered are summarized in [Table 2](#T2){ref-type="table"}. All patients were eligible for response evaluation. The mean number of chemotherapy cycles administered was 3.8 (range, 2 to 9) in the PLD monotherapy group and 7 (range, 2 to 13) in the PLD-C group. ORR and CBR were 5.0% and 17.5% in the PLD monotherapy group and 33.3% and 75.0% in the PLD-C group, respectively. Kaplan-Meier curves for PFS in each group are presented in [Fig. 1](#F1){ref-type="fig"}. The mean PFS was 5 months in the PLD monotherapy group and 13 months in the PLD-C group. At 6 months after treatment initiation, no disease progression was noted in 6 (15%) patients of the PLD monotherapy group and 10 (83.3%) patients of the PLD-C group. Moreover, 27 (67.5%) patients of the PLD monotherapy group and one (8.3%) patient of the PLD-C group died during the treatment period.

Adverse events according to chemotherapy regimens are summarized in [Table 3](#T3){ref-type="table"}. Hematological adverse events such as neutropenia and thrombocytopenia were more common in the PLD-C group (*P*\<0.001 and *P*=0.004). The incidence of anemia and non-hematological adverse events such as mucositis, HFS, and allergic reactions was similar in both groups. The prevalence of mucositis and HFS was 10.3% and 9.0% in the PLD monotherapy group and 16.7% and 14.3% in the PLD-C group, respectively. Three (7.5%) patients from the PLD monotherapy group and 6 (50%) from the PLD-C group received dose reduction in chemotherapy because of adverse events; furthermore, 1 patient discontinued PLD monotherapy because of severe continuous HFS above grade 3.

Discussion
==========

PLD-C therapy exhibited better therapeutic effects than PLD monotherapy, which of course caused by the differences of baseline predictive factors on survival, such as treatment-free interval, number of previous chemotherapy regimens, and platinum sensitivity. Approximately half of the patients of the PLD monotherapy group had previously received more than 3 chemotherapy regimens, and treatment was initiated at \<1 month after failure of the previous chemotherapy.

In the PLD monotherapy group, ORR and CBR were 5.0% and 17.5%, respectively. [Table 4](#T4){ref-type="table"} presents a comparison of efficacy of PLD monotherapy with different studies \[[@B11][@B14][@B15]\], and the results of this study are poorer than those of other studies. While the average number of previous chemotherapy regimens of other studies was less than 2, the patients in the present study had an average of 3.5 previous chemotherapy regimens; the marked difference in this basic factor appears to have affected the response rate. However, in actual clinical situations, PLD monotherapy is administered to patients with advanced disease; thus, several patients have a history of more than 3 previous chemotherapy regimens. Despite the differences in response rates, there was no significant difference in the time to progression among the aforementioned studies from 4 to 5 months. Considering these results, the effectiveness of PLD appears to be largely dependent on the pretreatment differences in the baseline predictive factors and does not appear to be considerably influenced by racial differences.

PLD therapy is clinically administered at various doses in the range of 30--50 mg/m^2^; thus, the available evidence should be carefully interpreted because the efficacy and adverse effects may vary. The present study was conducted with a maximum tolerated dose of 50 mg/m^2^, but certain studies have reported similar efficacy and lower toxicity with doses of 40 mg/m^2^ \[[@B16][@B17]\]. According to the results of this study, the efficacy of PLD monotherapy in platinum-resistant ROC does not appear to be more than expected; therefore, it might be worthwhile to consider a lower dose of treatment that can reduce toxicity without significantly decreasing the efficacy, and a comparative study of the therapeutic effect and side effects of each dose in Asian women is required.

In combination therapy with carboplatin, dose reductions were more frequent and the incidence of hematological adverse events such as neutropenia and thrombocytopenia was higher. Anemia appears to have been largely unaffected by the use of prophylactic iron supplements during treatment. There was no significant difference was observed in the incidence of non-hematological adverse events such as mucositis or HFS; this may be due to the use of the same dose of PLD in both groups. HFS is considered to be the dose-limiting toxicity of PLD therapy \[[@B18]\]. Only one patient with PLD monotherapy discontinued treatment after the fifth injection because of severe continuous HFS above grade 3; she rested afterward, and disease progression was observed 3 months after discontinuation. Other patients who had mucositis or HFS showed improvement in symptoms and continued treatment after delayed dosing and dose reduction.

This study had some limitations of note. It was a retrospective study and there could be a bias by its nature. Because the PLD treatment was only recently approved in Korea, the number of PLD-C groups was small because of PLD is often used in patients who had already acquired platinum resistance. In this study, left ventricular ejection fraction was not routinely checked for all patients. Cardiotoxicity is a major concern with anthracyclines; however, the liposomal envelope of PLD leads to low doses of free doxorubicin in the normal tissue and lowers its toxicity profile \[[@B19][@B20]\]. Several studies have reported low cardiotoxicity with PLD; thus, monitoring of cardiotoxicity is not necessarily required for patients receiving PLD therapy who do not have any cardiac symptoms \[[@B21][@B22][@B23]\]. Moreover, none of the study patients complained any signs or symptoms of cardiac abnormality.

In conclusion, this study demonstrated the efficacy and safety of PLD monotherapy and PLD-C in Korean patients with ROC. To the best of our knowledge, this is the first retrospective study on PLD monotherapy in Asian patients. PLD monotherapy is widely used as a salvage therapy with anti-tumor activity in patients with platinum-resistant ROC. According to the results of this study, the efficacy of PLD monotherapy in platinum-resistant ROC appears to be largely dependent on pretreatment differences in baseline predictive factors. This study would be helpful to consider the degree of worry about side effects and treatment expectations after the treatment. Further additional retrospective studies with larger patient samples are needed to confirm the efficacy of PLD monotherapy in Asian patients with platinum-resistant ROC.

**Conflict of interest:** No potential conflict of interest relevant to this article was reported.

![PFS in each group. PFS, progression-free survival; PLD, pegylated liposomal doxorubicin; PLD-C, pegylated liposomal doxorubicin combined with carboplatin.](ogs-60-433-g001){#F1}

###### Baseline characteristics of subgroups according to the chemotherapy regimens

![](ogs-60-433-i001)

  Variables                                 No. of patients (%)   *P*-value   
  ----------------------------------------- --------------------- ----------- -------
  Median age (yr)                           57.0                  58.0        0.230
  Initial FIGO stage                                                          0.858
   Unknown                                  3 (25.0)              3 (7.5)     
   I--II                                    0 (0)                 6 (15.0)    
   III--IV                                  9 (75.0)              31 (77.5)   
  Histological subtype                                                        0.687
   Serous                                   11 (91.7)             38 (95.0)   
   Serous                                   1 (8.3)               2 (5.0)     
  Largest lesion before chemotherapy (mm)                                     0.858
   Non-measurable                           3 (25.0)              9 (22.5)    
   ≤20                                      0 (0)                 4 (10.0)    
   \>20                                     9 (75.0)              27 (67.5)   
  CA-125 level (U/mL)                                                         0.391
   \<50                                     1 (8.3)               6 (15.0)    
   51--100                                  4 (33.3)              6 (15.0)    
   100--1,000                               6 (50.0)              19 (47.5)   
   \>1,000                                  1 (8.3)               9 (22.5)    
  Treatment-free interval (mon)                                               0.002
   Mean                                     10.7                  3.7         
   \<1                                      0 (0)                 16 (40.0)   
   1--6                                     0 (0)                 16 (40.0)   
   \>6                                      12 (100.0)            8 (20.0)    
  No. of previous chemotherapy regimens                                       0.001
   ≤3                                       12 (100)              21 (52.5)   
   \>3                                      0 (0)                 19 (47.5)   

PLD, pegylated liposomal doxorubicin; PLD-C, pegylated liposomal doxorubicin combined with carboplatin; FIGO, International Federation of Gynecology and Obstetrics; CA-125, cancer antigen 125.

###### Response of subgroups according to the chemotherapy regimens
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  Variables                          No. of patients (%)   
  ---------------------------------- --------------------- -----------
  Measurable disease (RECIST 1.1)                          
   CR                                2 (16.7)              1 (2.5)
   PR                                2 (16.7)              0 (0)
   SD                                5 (41.7)              8 (20.0)
   PD                                3 (25.0)              31 (77.5)
  CA-125                                                   
   Response                          9 (75.0)              8 (20.0)
   No response                       3 (25.0)              32 (80.0)
  Overall response (GCIG criteria)                         
   CR                                2 (16.7)              1 (2.5)
   PR                                2 (16.7)              1 (2.5)
   SD                                5 (41.7)              5 (12.5)
   PD                                3 (25.0)              33 (82.5)
  Response rate (CR + PR)            4 (33.3)              2 (5.0)
  CBR (CR + PR + SD)                 9 (75.0)              7 (17.5)
  Death                              1 (8.3)               27 (67.5)

PLD, pegylated liposomal doxorubicin; PLD-C, pegylated liposomal doxorubicin combined with carboplatin; RECIST, Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; CA-125, cancer antigen 125; GCIG, Gynecologic Cancer Intergroup; CBR, clinical benefit rate.

###### Adverse events according to the chemotherapy regimens
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  Adverse event                  PLD-C (total 84 cycles)   Single PLD (total 155 cycles)   *P*-value
  ------------------------------ ------------------------- ------------------------------- -----------
  Hematological (grade 3, 4)                                                               
   Neutropenia                   22 (26.2)                 11 (7.1)                        \<0.001
   Anemia                        7 (8.3)                   7 (4.5)                         0.230
   Thrombocytopenia              11 (13.1)                 5 (3.2)                         0.004
  Non-hematological (grade ≥2)                                                             
   Mucositis                     14 (16.7)                 16 (10.3)                       0.158
   HFS                           12 (14.3)                 14 (9.0)                        0.213
   Allergic reactions            1 (1.2)                   1 (0.6)                         0.659

PLD, pegylated liposomal doxorubicin; PLD-C, pegylated liposomal doxorubicin combined with carboplatin; HFS, hand-foot syndrome.

###### Comparison of efficacy of PLD monotherapy with that reported in other studies
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  Study                                No. of prior chemotherapy regimens   ORR (%)   CBR (%)   Time to progression (mon)
  ------------------------------------ ------------------------------------ --------- --------- ---------------------------
  Katsumata et al. \[[@B11]\] (n=62)   1.8                                  21.0      61.2      5.5
  Gordon et al. \[[@B14]\] (n=40)      1.9                                  7.7       57.5      4.0
  Mayer et al. \[[@B15]\] (n=34)       1.5                                  7.5       NA        4.0
  This study (n=40)                    3.5                                  5.0       17.5      5.0

PLD, pegylated liposomal doxorubicin; ORR, objective response rate; CBR, clinical benefit rate; NA, not applicable.
